Literature DB >> 30836341

Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro.

Negar Sadeghi1, Robbert Jan Kok, Clemens Bos, Maurice Zandvliet, Willie J C Geerts, Gert Storm, Chrit T W Moonen, Twan Lammers, Roel Deckers.   

Abstract

Hypoxia is a characteristic feature of solid tumors and an important cause of resistance to radiotherapy. Hypoxic cell radiosensitizers have been shown to increase radiotherapy efficacy, but dose-limiting side effects prevent their widespread use in the clinic. We propose the encapsulation of hypoxic cell radiosensitizers in temperature-sensitive liposomes (TSL) to target the radiosensitizers specifically to tumors and to avoid unwanted accumulation in healthy tissues. The main objective of the present study is to develop and characterize TSL loaded with the radiosensitizer pimonidazole (PMZ) and to evaluate the in vitro efficacy of free PMZ and PMZ encapsulated in TSL in combination with hyperthermia and radiotherapy. PMZ was actively loaded into TSL at different drug/lipid ratios, and the physicochemical characteristics and the stability of the resulting TSL-PMZ were evaluated. PMZ release was determined at 37 °C and 42 °C in HEPES buffer saline and fetal bovine serum. The concentration-dependent radiosensitizing effect of PMZ was investigated by exposing FaDu cells to different PMZ concentrations under hypoxic conditions followed by exposure to ionizing irradiation. The efficacy of TSL-PMZ in combination with hyperthermia and radiotherapy was determined in vitro, assessing cell survival and DNA damage by means of the clonogenic assay and histone H2AX phosphorylation, respectively. All TSL-PMZ formulations showed high encapsulation efficiencies and were stable for 30 d upon storage at 4 °C and 20 °C. Fast PMZ release was observed at 42 °C, regardless of the drug/lipid ratio. Increasing the PMZ concentration significantly enhanced the effect of ionizing irradiation. Pre-heated TSL-PMZ in combination with radiotherapy caused a 14.3-fold increase in cell death as compared to radiotherapy treatment alone. In conclusion, our results indicate that TSL-PMZ in combination with hyperthermia can assist in improving the efficacy of radiotherapy under hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30836341     DOI: 10.1088/1361-6528/ab0ce6

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  4 in total

1.  A Comprehensive Evaluation of ZrC Nanoparticle in Combined Photothermal and Radiation Therapy for Treatment of Triple-Negative Breast Cancer.

Authors:  Shan Jiang; Zhao Liu; Yuhang Tian; Ming Zhuang; Shiqi Piao; Yan Gao; Andrew Tam; Hongtao Hu; Wen Cheng
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

Review 2.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

3.  Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.

Authors:  Brittany Epp-Ducharme; Michael Dunne; Linyu Fan; James C Evans; Lubabah Ahmed; Pauric Bannigan; Christine Allen
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

Review 4.  Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy.

Authors:  Eliza Rocha Gomes; Marina Santiago Franco
Journal:  Pharmaceutics       Date:  2022-01-03       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.